What Happened?
San Francisco, CA-based Alector Appointed Arnon Rosenthal as Chief Executive Officer
About the Company
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
About the Person
Arnon Rosenthal received his Ph.D. from the Hebrew University Jerusalem, Israel, and then conducted a postdoctoral fellowship at Genentech, Inc. Following his postdoc, he was appointed to a scientist position at Genentech Inc., and was later promoted to a senior scientist and then to staff scientist and permanent member of Genentech Research Review Committee. Dr. Rosenthal is co-founder of Rinat Neuroscience, a privately-held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders, where he also served as President, board member and CSO. Rinat was acquired by Pfizer with several drugs in clinical development, including Tanezumab which is currently in Phase 3 for multiple pain indications, PF-04360365 which entered Phase 2 for Alzheimer`s disease and RN-307 which entered the clinic for migraine. Dr. Rosenthal is also co-founder and board chair of Annexon Biosciences and co-founder, President and CEO of Alector LLC, a privately held biotechnology company focused on the discovery and development of novel therapies for Alzheimer`s disease and other forms of dementia. Dr. Rosenthal is a visiting professor of the Department of Anatomy at the University of California San Francisco and a member of the scientific advisory boards of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He has co-authored 108 scientific publications and over 380 issued patents and applications.
Info Source
Press Release
Short Profile